Cancer treatment maker BioCold Genesys lands $22M in funds

Cold Genesys Inc., a biopharmaceutical company developing novel immunotherapies used to treat cancer, has closed on $22 million in financing. The Santa Ana, California-based company said the series C round was in the form of preferred stock. New investors participated in the round, including lead investor ORI Healthcare Fund L.P., with participation from Perseverance Capital Management. Cold Genesys said the financing will allow it to accelerate its ongoing clinical programs and the continued advancement…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news